Adverum reveals positive results from Phase 1 trial of ADVM-022
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum reveals positive results from Phase 1 trial of ADVM-022

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD.

Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announced the demonstration of positive 24-week clinical data. Apparently, the data was obtained from the initial cohort of patients treated with a one-time IVT (intravitreal) dosage of ADVM-022 in the OPTIC phase 1 clinical study in wet AMD (age-related macular degeneration).

According to reliable sources, patients who participated in this cohort gained progress in retinal anatomy and vision maintenance, without the requirement of anti-VEGF rescue injections, after a one-time IVT dose of the drug.

Reportedly, these patients earlier needed numerous anti-VEGF injections to maintain functional vision and to regulate their wet AMD. Moreover, the data is slated to be presented in September, by Szilárd Kiss, M.D., retinal specialist & the presenter for the meeting, at a podium presentation during the Retina Society 2019 Annual Meeting.

Speaking on the move, Kiss said that generally people with wet AMD need repeated anti-VEGF injections to sustain vision, representing a significant treatment load which often ends in vision loss due to lack of treatment. A long-term anti-VEGF treatment would significantly fulfill the clinical need for these patients.

He added that the material frequent injections to on ADVM-022 are promising, as they successfully show that a one-time gene therapy treated by IVT injection has the capacity to improve the treatment paradigm for patients with wet AMD and offer sustained efficacy.

As for Aaron Osborne, MBBS, Chief Medical Officer, Adverum, the company is happy to declare that there was no need for the rescue injections in this cohort of patients through 24 weeks. He claims that patient earlier needed numerous injections to prevent vision loss. Morever, a single injection of ADVM-022 resulted in constant anatomical vision maintenance and advancements.

Source Credit: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-reports-positive-24-week-data-first

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...